We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetics “Cloud” Designed to Create Opportunities for Researchers and Clinicians

By LabMedica International staff writers
Posted on 22 Sep 2011
Gene sequencing and analysis could be drastically speeded up, leading to patients receiving a faster and more accurate diagnosis, according to a recent project’s investigators.

Using cloud-computing technology, the researchers have found they can cut the amount of time it takes to store the huge amounts of data generated when individual genes are sequenced and analyzed. More...
Whereas at the moment this process can take up to three months, the scientists believe their new technique could mean results are generate in approximately one week.

Eagle Genomics, Ltd., a leading open-source bioinformatics service provider, is conducting the research in collaboration with the University of Manchester (UK), and Cytocell, Ltd. (Cambridge, UK), with assistance from National Genetics Reference Laboratories (NGRL), based at the Central Manchester University Hospitals NHS (National Health Service) Foundation Trust, and the NIHR Manchester Biomedical Research Center. The GBP 500,000 project is part-funded by the UK’s national innovation agency, the Technology Strategy Board.

Access to the data analyzed and stored by the cloud will enable medical researchers who are developing and testing new treatments to compare large amounts of information and find common genetic links. The technology will also help clinicians to look at an individual patient’s genetic composition to aid diagnosis and ongoing treatment. Instead of simply testing a patient for one suspected condition, using the cloud technology could allow clinicians to test for a much wider range of complaints. Currently, the NHS information technology (IT) systems do not have the resources to cope with the huge demands required. The cloud system can be accessed from a separate site, away from hospitals, freeing up space.

The project will build upon the success of the Taverna Workflow Management System software developed by Prof. Carole Goble’s myGrid team at the University of Manchester. Eagle Genomics will work with the University to adapt Taverna to allow non-IT experts to easily add and extract information and share it with their colleagues. “Taverna is ideal for this project because it allows you to systematically automate the analysis processes of expert geneticists and make them easily available for other to use at the press of a button,” said Prof. Andy Brass, from the University of Manchester.

Example applications identified and described by NGRL and Cytocell will provide a significant and valuable resource to help develop and demonstrate the efficacy of the resulting system. “Genetic sequencing is an increasingly important diagnostic tool as well as being fundamental to many areas of research,” said Prof. Graeme Black, director of the NIHR Manchester Biomedical Research Center and a consultant at Manchester Royal Eye Hospital. “By storing genetic data in the ‘cloud’ indefinitely, we can use it for research studies and also to help clinicians to decide if medical conditions, that patients develop at any stage, may be linked to their genes.”

Abel Ureta-Vidal, CEO of Eagle Genomics Ltd., added, “Thanks to funding from the Technology Strategy Board, this project is looking at ways in which genetic data can be securely and confidentially stored, accessed, and analyzed only by approved users.”

The project, which started in July 2011, is on target for completion of a fully functional system with an initial selection of analyses available by December 2012.

Eagle Genomics is an outsourced bioinformatics services and software company specializing in genome content management and the provision of open-source solutions.

The myGrid tools support the creation of e-laboratories and they have been used in domains as diverse as systems biology, social science, music, astronomy, multimedia, and chemistry.

Cytocell is a leading European developer and manufacturer of in-situ hybridization (FISH) probes for use in both routine cytogenetics and in the analysis and classification of cancers.

Related Links:

Eagle Genomics
University of Manchester
UK National Genetics Reference Laboratories




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.